Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALKSNASDAQ:IMGNNASDAQ:IONSNASDAQ:UTHR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALKSAlkermes$28.81-0.1%$29.98$22.90▼$36.45$4.75B0.471.72 million shs2.94 million shsIMGNImmunoGen$31.23$31.23$3.61▼$31.25$8.32B1.188.78 million shs40 shsIONSIonis Pharmaceuticals$39.80+0.1%$33.97$23.95▼$52.34$6.33B0.181.58 million shs2.48 million shsUTHRUnited Therapeutics$284.27+0.1%$301.12$250.60▼$417.82$12.82B0.57444,323 shs462,927 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALKSAlkermes0.00%-0.96%-6.61%-12.75%+19.54%IMGNImmunoGen0.00%0.00%0.00%0.00%0.00%IONSIonis Pharmaceuticals0.00%+6.39%+18.31%+31.92%-16.49%UTHRUnited Therapeutics0.00%-2.23%-10.14%-7.79%-10.76%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALKSAlkermes4.8987 of 5 stars4.43.00.04.22.82.51.9IMGNImmunoGenN/AN/AN/AN/AN/AN/AN/AN/AIONSIonis Pharmaceuticals4.5371 of 5 stars4.42.00.03.02.53.30.6UTHRUnited Therapeutics4.9926 of 5 stars4.35.00.04.62.73.32.5Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALKSAlkermes 2.83Moderate Buy$40.0038.84% UpsideIMGNImmunoGen 0.00N/AN/AN/AIONSIonis Pharmaceuticals 2.72Moderate Buy$57.8845.41% UpsideUTHRUnited Therapeutics 2.69Moderate Buy$393.0838.28% UpsideCurrent Analyst Ratings BreakdownLatest UTHR, IONS, ALKS, and IMGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/26/2025IONSIonis PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$50.006/17/2025ALKSAlkermesUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$33.00 ➝ $42.006/12/2025IONSIonis PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$45.00 ➝ $48.006/11/2025UTHRUnited TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$321.00 ➝ $315.006/2/2025UTHRUnited TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$405.005/28/2025ALKSAlkermesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral ➝ Buy$45.005/20/2025IONSIonis PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$50.00 ➝ $50.005/13/2025ALKSAlkermesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/5/2025UTHRUnited TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$425.00 ➝ $425.005/2/2025ALKSAlkermesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral5/2/2025ALKSAlkermesRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Perform ➝ Sector Perform$39.00 ➝ $40.00(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALKSAlkermes$1.56B3.05$2.65 per share10.87$9.05 per share3.18IMGNImmunoGen$287.61M28.91N/AN/A$0.71 per share43.99IONSIonis Pharmaceuticals$705M8.99N/AN/A$3.73 per share10.67UTHRUnited Therapeutics$2.88B4.46$28.40 per share10.01$144.34 per share1.97Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALKSAlkermes$367.07M$2.0913.7821.031.7923.30%27.52%17.98%7/23/2025 (Estimated)IMGNImmunoGen-$222.93M-$0.31N/A84.41N/A-25.56%-22.11%-13.53%N/AIONSIonis Pharmaceuticals-$453.90M-$2.99N/AN/AN/A-63.65%-91.85%-15.77%7/30/2025 (Estimated)UTHRUnited Therapeutics$1.20B$25.0611.3410.346.2240.44%19.33%16.73%7/30/2025 (Estimated)Latest UTHR, IONS, ALKS, and IMGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/23/2025Q2 2025ALKSAlkermes$0.42N/AN/AN/A$343.20 millionN/A5/1/2025Q1 2025ALKSAlkermes$0.32$0.13-$0.19$0.13$307.53 million$306.51 million4/30/2025Q1 2025IONSIonis Pharmaceuticals-$1.07-$0.93+$0.14-$0.93$144.31 million$132.00 million4/30/2025Q1 2025UTHRUnited Therapeutics$6.29$6.63+$0.34$6.63$726.82 million$794.40 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALKSAlkermesN/AN/AN/AN/AN/AIMGNImmunoGenN/AN/AN/AN/AN/AIONSIonis PharmaceuticalsN/AN/AN/AN/AN/AUTHRUnited TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALKSAlkermesN/A3.332.92IMGNImmunoGen0.135.705.65IONSIonis Pharmaceuticals2.639.669.62UTHRUnited TherapeuticsN/A5.465.23Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALKSAlkermes95.21%IMGNImmunoGen90.50%IONSIonis Pharmaceuticals93.86%UTHRUnited Therapeutics94.08%Insider OwnershipCompanyInsider OwnershipALKSAlkermes4.40%IMGNImmunoGen5.07%IONSIonis Pharmaceuticals2.71%UTHRUnited Therapeutics10.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALKSAlkermes1,800164.90 million157.65 millionOptionableIMGNImmunoGen277266.26 million252.76 millionOptionableIONSIonis Pharmaceuticals1,069159.16 million154.85 millionOptionableUTHRUnited Therapeutics1,30545.11 million40.46 millionOptionableUTHR, IONS, ALKS, and IMGN HeadlinesRecent News About These CompaniesPaul A. Mahon Sells 11,000 Shares of United Therapeutics Corporation (NASDAQ:UTHR) StockJune 29 at 4:19 AM | americanbankingnews.comUnited Therapeutics Corporation (UTHR) - Yahoo FinanceJune 28 at 2:23 PM | finance.yahoo.comUnited Therapeutics Corporation (NASDAQ:UTHR) EVP Paul A. Mahon Sells 11,000 SharesJune 28 at 6:13 AM | insidertrades.comUnited Therapeutics Announces World’s First Bioengineered External Liver Treatment in Clinical StudyJune 28 at 5:24 AM | msn.comUTHR United Therapeutics Corporation - Seeking AlphaJune 27 at 7:22 PM | seekingalpha.comInsider Selling: United Therapeutics Corporation (NASDAQ:UTHR) EVP Sells 11,000 Shares of StockJune 27 at 5:55 PM | marketbeat.comUnited Therapeutics Corporation (NASDAQ:UTHR) Shares Bought by Achmea Investment Management B.V.June 27 at 8:19 AM | marketbeat.comRobeco Institutional Asset Management B.V. Buys 34,362 Shares of United Therapeutics Corporation (NASDAQ:UTHR)June 27 at 5:02 AM | marketbeat.comContrasting United Therapeutics (NASDAQ:UTHR) and Journey Medical (NASDAQ:DERM)June 27 at 2:26 AM | americanbankingnews.comUnited Therapeutics’ Ralinepag Study: A Potential Game-Changer in PAH TreatmentJune 26, 2025 | tipranks.comWhy United Therapeutics (UTHR) is a Top Value Stock for the Long-TermJune 26, 2025 | zacks.com3D Systems and TISSIUM Achieve FDA Approval for Innovative 3D-Printed Solution in Peripheral Nerve RepairJune 26, 2025 | quiverquant.comQUnited Therapeutics Corporation (NASDAQ:UTHR) Director Sells $187,043.55 in StockJune 26, 2025 | insidertrades.comBrokerages Set United Therapeutics Corporation (NASDAQ:UTHR) Price Target at $393.08June 26, 2025 | americanbankingnews.comInsider Sell: Nilda Mesa Sells Shares of United Therapeutics CorpJune 25, 2025 | gurufocus.comUnited Therapeutics Corporation (NASDAQ:UTHR) Director Sells $187,043.55 in StockJune 25, 2025 | marketbeat.comUnited Therapeutics Corporation (NASDAQ:UTHR) Director Sells 3,036 Shares of StockJune 25, 2025 | marketbeat.com5 Must-Read Analyst Questions From United Therapeutics’s Q1 Earnings CallJune 25, 2025 | msn.comOppenheimer Asset Management Inc. Has $5.28 Million Stock Position in United Therapeutics Corporation (NASDAQ:UTHR)June 25, 2025 | marketbeat.comUnited Therapeutics and Intermountain Health Announce the First Patient Treated With External Liver Support Using a Bioengineered LiverJune 24, 2025 | bakersfield.comBUnited Therapeutics’ Ralinepag Study: A Potential Game-Changer for PAH TreatmentJune 24, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAST SpaceMobile’s Star Is Rising: Get in While It’s Still Cheap!By Thomas Hughes | June 16, 2025View AST SpaceMobile’s Star Is Rising: Get in While It’s Still Cheap!Analysts Supercharge AMD Stock Ahead of Q2 AI CatalystBy Thomas Hughes | June 26, 2025View Analysts Supercharge AMD Stock Ahead of Q2 AI CatalystAs Oil Prices Rebound, These Stocks Could Fuel the Next RallyBy Sarah Horvath | June 9, 2025View As Oil Prices Rebound, These Stocks Could Fuel the Next Rally3 Growth Stocks Too Small for Institutions to BuyBy Gabriel Osorio-Mazilli | June 19, 2025View 3 Growth Stocks Too Small for Institutions to BuyASML Keeps Buying Back Its Own Stock—Chasing Discount and UpsideBy Gabriel Osorio-Mazilli | June 25, 2025View ASML Keeps Buying Back Its Own Stock—Chasing Discount and UpsideUTHR, IONS, ALKS, and IMGN Company DescriptionsAlkermes NASDAQ:ALKS$28.81 -0.02 (-0.07%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$29.24 +0.43 (+1.49%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.ImmunoGen NASDAQ:IMGNImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts. As of February 12, 2024, ImmunoGen, Inc. operates as a subsidiary of AbbVie Inc.Ionis Pharmaceuticals NASDAQ:IONS$39.80 +0.02 (+0.05%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$40.35 +0.55 (+1.38%) As of 04:06 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.United Therapeutics NASDAQ:UTHR$284.27 +0.18 (+0.06%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$250.60 -33.67 (-11.84%) As of 04:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Snowflake Hits 52-Week High—Options Traders Bet on Further Rally Addition by Subtraction: Intel’s New Strategy Energizes Investors Apple: The Mag 7’s Dead Money Stock or AI Cash Cow in the Making? NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Rocket Lab: Europe Comes Calling as Momentum Builds Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
